Literature DB >> 5666962

Catabolic origin of a Bence Jones protein fragment.

D Cioli, C Baglioni.   

Abstract

Gel filtration analysis of the urinary proteins of some patients with myeloma has shown the presence of "fragments" of Bence Jones proteins which correspond to the variable half of these proteins. Experiments have been carried out to establish the origin of a "fragment" observed in a patient who excreted a large amount of this protein. Labeled homologous Bence Jones protein has been injected into this and other control patients. Excretion of labeled "fragment" has been observed in all. Analysis by peptide mapping and radio-autography of this labeled "fragment" isolated from the urine showed that the invariable half of the Bence Jones protein was not excreted; it seemed thus likely that the invariable half was metabolized to small peptides and free amino acids. A labeled Bence Jones protein which was excreted without any accompanying "fragment" was injected into the patient who excreted large amounts of "fragment." No excretion of labeled "fragment" was observed. It was thus concluded that the property of being degraded to "fragment" is characteristic of some "fragile" Bence Jones proteins and is not determined by the patient. Incubation with serum or urine of the "fragile" Bence Jones protein failed to produce any "fragment." "Fragments" of Bence Jones proteins are thus most likely formed during excretion of these proteins through the kidney and are products of the catabolism of Bence Jones proteins.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5666962      PMCID: PMC2138528          DOI: 10.1084/jem.128.3.517

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  14 in total

1.  Structural relationships among normal human gamma-globulin, myeloma globulins, and Bence-Jones proteins.

Authors:  F W PUTMAN
Journal:  Biochim Biophys Acta       Date:  1962-10-08

2.  Synthesis of the gamma-G heavy chain in rabbit lymph node cells.

Authors:  J B Fleischman
Journal:  Biochemistry       Date:  1967-05       Impact factor: 3.162

3.  Biosynthetic units of an immunoglobulin heavy chain.

Authors:  P M Knopf; R M Parkhouse; E S Lennox
Journal:  Proc Natl Acad Sci U S A       Date:  1967-12       Impact factor: 11.205

4.  On the localisation of antigenic determinants in a Bence Jones protein.

Authors:  H G van Eyk; K Myszkowska
Journal:  Clin Chim Acta       Date:  1967-11       Impact factor: 3.786

5.  Antigenic analysis of an N-terminal fragment of a type k Bence Jones protein.

Authors:  M Tan; W Epstein
Journal:  J Immunol       Date:  1967-03       Impact factor: 5.422

6.  Low-molecular-weight proteins related to Bence Jones proteins in multiple myeloma.

Authors:  A Solomon; J Killander; H M Grey; H G Kunkel
Journal:  Science       Date:  1966-03-11       Impact factor: 47.728

7.  Low molecular weight L-chain components related to Bence-Jones proteins.

Authors:  R C Williams; S R Pinnell; G T Bratt
Journal:  J Lab Clin Med       Date:  1966-07

8.  Origin of structural variation in Bence Jones proteins.

Authors:  D Cioli; C Baglioni
Journal:  J Mol Biol       Date:  1966-01       Impact factor: 5.469

9.  A study of immunoglobulin structure. I. The fingerprinting of aminoethylated Bence-Jones proteins.

Authors:  C Baglioni; M La Via; V Ventruto
Journal:  Biochim Biophys Acta       Date:  1965-12-16

10.  A study of immunoglobulin structure. II. The comparison of Bence Jones proteins by peptide mapping.

Authors:  C Baglioni; D Cioli
Journal:  J Exp Med       Date:  1966-09-01       Impact factor: 14.307

View more
  2 in total

1.  Properties of halves of immunoglobulin light chains.

Authors:  F A Karlsson; P A Peterson; I Berggard
Journal:  Proc Natl Acad Sci U S A       Date:  1969-12       Impact factor: 11.205

2.  Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy.

Authors:  A Solomon; C L McLaughlin; J D Capra
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.